Parkinson's drug access expanded for patients with key gene mutation
Disease control
AVAILABLE
This program offers free continued treatment with BIA 28-6156 to people with Parkinson's disease who have a specific change in the GBA1 gene and have already finished the ACTIVATE study. The goal is to provide ongoing access to the study drug while monitoring safety and effects. …
Sponsor: Bial R&D Investments, S.A. • Aim: Disease control
Last updated May 17, 2026 04:12 UTC